export default function SS31OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        SS-31 (elamipretide) is the most clinically advanced mitochondria-targeted peptide in existence &mdash; it has actual human Phase 2 trial data showing improved cardiac energy efficiency in heart failure patients. It works by protecting a specific fat molecule inside mitochondria that keeps the cellular power generators running efficiently. Community use extrapolates from those disease trials toward healthy aging and performance. There&rsquo;s one critical quality issue: SS-31 requires a specific D-amino acid structure to work; most gray-market products can&rsquo;t prove they have it.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Energy and Fatigue Person &mdash; mitochondria curiosity, chronic fatigue, aging</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I keep hearing that mitochondria are the key to aging and energy &mdash; is SS-31 actually the thing that works, or is this another supplement marketing story?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It has real human clinical evidence &mdash; unlike almost every other &ldquo;mitochondria compound&rdquo;</strong><br />The HARP trial showed measurable improvement in how efficiently heart muscle uses energy, measured with cardiac MRI spectroscopy &mdash; not subjective questionnaires. For a compound in this space, human evidence at any level is rare. SS-31 has it.</li>
          <li><strong>The mechanism targets something real about how mitochondria age</strong><br />As mitochondria age, a critical fat molecule inside them (cardiolipin) gets damaged by oxidation, which disrupts the energy-making machinery. SS-31 specifically protects cardiolipin. This is a targeted fix for a documented aging mechanism, not a vague &ldquo;supports mitochondria&rdquo; claim.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The HARP trial was done in people with heart failure using continuous IV infusion in a hospital setting &mdash; very different from someone injecting subcutaneously at home for general energy. Whether that translates to benefit in a healthy person with no mitochondrial disease is unknown. Mitochondrial function improvement is subtle and cumulative; this is not going to make you feel different the next day. The quality issue is real: if the gray-market product you buy uses standard amino acids instead of the D-form variants that SS-31 requires, it degrades quickly and doesn&rsquo;t work. Net: the most compelling mitochondrial peptide available, but the clinical context and product quality constraints are serious.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Endurance Athlete &mdash; mitochondrial performance, VO2 max, recovery</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;If SS-31 improves mitochondrial efficiency in heart failure patients, could it improve mitochondrial output in trained athletes?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Mitochondrial function is rate-limiting for endurance performance</strong><br />VO2 max is ultimately limited by how efficiently mitochondria in heart and muscle can use oxygen. Any compound that improves mitochondrial energy efficiency is theoretically relevant to endurance capacity. The HARP trial measured exactly this kind of efficiency improvement, just in a diseased heart rather than a healthy one.</li>
          <li><strong>High-intensity training produces mitochondrial oxidative stress</strong><br />Heavy training generates the same kind of reactive oxygen species that damage cardiolipin in aging mitochondria. The idea that SS-31 could protect mitochondria during training-induced oxidative stress has a logical basis, even without athlete-specific data.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">In people whose mitochondria are functioning normally, you&rsquo;re not fixing a defect &mdash; you&rsquo;re trying to optimize a system that evolution has already optimized for performance under load. Whether SS-31 provides meaningful additional benefit in a healthy trained athlete whose mitochondrial function is already well-supported by training adaptations is not tested. If you can&rsquo;t verify D-amino acid content in your product, you may be injecting something that degrades in minutes rather than reaching your mitochondria. This is the wrong compound for muscle growth or body composition goals. Net: mechanistically plausible for endurance context, no athlete-specific evidence, product quality makes or breaks the whole question.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Longevity Mitochondrial Biohacker &mdash; cardiolipin biology, aging mechanisms, ETC function</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;What does the cardiolipin peroxidation mechanism actually tell us about mitochondrial aging, and how does the HARP trial PCr/ATP result translate to the longevity context?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Cardiolipin biology is central to the mitochondrial aging story</strong><br />Cardiolipin is the signature phospholipid of the inner mitochondrial membrane and is essential for electron transport chain complex assembly and efficiency. Age-related cardiolipin peroxidation is documented in cardiac and skeletal muscle tissue. SS-31&rsquo;s mechanism &mdash; selectively concentrating in the inner membrane to prevent cardiolipin oxidation &mdash; directly addresses one of the most characterized molecular mechanisms of mitochondrial aging.</li>
          <li><strong>The HARP trial PCr/ATP result is genuinely meaningful data</strong><br />Phosphocreatine to ATP ratio measured by cardiac MRI spectroscopy is a direct measure of cardiac energy reserve &mdash; not a surrogate. Showing that a 28-day infusion course improved this ratio in HFpEF patients is mechanistic proof that SS-31 actually changes mitochondrial bioenergetics in human tissue. That kind of mechanistic human validation is rare in this space.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The leap from HFpEF Phase 2 data to healthy aging benefit is large &mdash; in heart failure, mitochondrial dysfunction is a major driver of disease, so there&rsquo;s a defect to fix. In healthy aging, mitochondrial dysfunction is more gradual and the benefit from supplementing a repair mechanism is less established. The D-amino acid requirement is particularly important for anyone serious about this compound: SS-31 contains D-arginine and a dimethylated tyrosine (Dmt) that resist proteolysis; a product made with standard L-arginine would have dramatically shorter half-life and likely wouldn&rsquo;t reach mitochondria at useful concentrations. Verify synthesis quality before drawing conclusions about efficacy. Net: the most scientifically credible mitochondrial peptide available, with meaningful human data and a specific verifiable quality requirement.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What SS-31 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A muscle growth or body composition compound &mdash; wrong mechanism entirely; it targets mitochondrial function, not hypertrophy</li>
              <li>Something you&rsquo;ll feel working the next day &mdash; mitochondrial efficiency improvement is subtle and cumulative</li>
              <li>Worth using if you can&rsquo;t verify D-amino acid content &mdash; a product with L-amino acids degrades quickly and doesn&rsquo;t work</li>
              <li>Proven for healthy aging or longevity &mdash; the human evidence is in disease states, not in healthy individuals</li>
              <li>Equivalent to CoQ10 or other mitochondrial supplements &mdash; the mechanism and specificity are categorically different</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The most clinically advanced mitochondria-targeted peptide &mdash; Phase 2 human data from the HARP trial showing real bioenergetic improvement</li>
              <li>Cardiolipin mechanism directly addresses one of the most documented molecular mechanisms of mitochondrial aging</li>
              <li>Inner mitochondrial membrane targeting is unusually specific &mdash; not a general antioxidant but a targeted repair signal</li>
              <li>Active clinical development for Barth syndrome (a genetic cardiolipin disease) validates the mechanism in human disease</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
